论文信息 - 3300 A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma - 字舞流文

3300 A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma

J. Sosman | R. Amaria | M. Postow | R. Carvajal | M. Carlino | A. Matano | S. Bhansali | L. Lam | F. Vos | A. Weise | H. Kalkavan | P. Yerramilli-Rao | C. V. Herpen